DURHAM, N.C., JULY 24, 2017 — Premier Research has named Kimberly Glen an Executive Director for Rare Disease, Strategic Development Department. She brings to the company nearly three decades of experience in contract research, drug development, and pharmaceutical consulting.
“Rare disease is an extremely demanding field of study, imposing unique challenges in patient recruitment, deriving conclusions from limited data, and helping customers achieve regulatory approval,” said Michael King Jolly, the company’s Senior Vice President for Strategic Development. “Kimberly’s extensive background in these areas will give our customers a significant advantage as they pursue treatments for these conditions.”
Ms. Glen was most recently Senior Director of Customer Governance at Medidata Solutions, and prior to that served as Vice President of the midsize pharma group at Quintiles. At Icon Clinical Research, she served as Vice President for Strategic Programs and Senior Director for Clinical Operations.
Within the pharma sector, Ms. Glen was Director of Clinical Operations at EMD Pharmaceuticals and XTL Biopharmaceuticals. She also spent several years as a clinical research consultant.
Ms. Glen holds a bachelor’s degree in social sciences from Campbell University.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,100 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.